An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Linifanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors AbbVie
- 02 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 01 Jul 2011 Planned end date changed from Jun 2011 to Dec 2011 as reported by ClinicalTrials.gov.